Sierra Oncology Inc
NASDAQ:SRRA
Sierra Oncology Inc
NASDAQ:SRRA
Price:
54.99 USD
Market Closed
Updated:
Apr 30, 2024
Section:
Relative Value
There is not enough data to reliably calculate the relative value of SRRA.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
SRRA
Relative Value
Base Case
Not Available
Valuation Multiples
Multiples Across Competitors
SRRA Competitors Multiples
Sierra Oncology Inc Competitors
Sierra Oncology Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CA |
|
Sierra Oncology Inc
NASDAQ:SRRA
|
1.3B USD | 0 | -12.7 | -10.2 | -10.1 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
281.9B USD | 5.2 | 58.5 | 12.7 | 19.4 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
146.2B USD | 5.2 | 21.8 | 16.2 | 24.3 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
102B USD | 10.3 | 28.2 | 22.5 | 23.6 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
97.7B USD | 7.4 | 24.7 | 16.3 | 18 | |
| AU |
|
CSL Ltd
ASX:CSL
|
132.9B AUD | 6.2 | 35.3 | 21.4 | 26.5 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
82.9B USD | 3.1 | 14.6 | 8 | 10.3 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
42.4B USD | 6.2 | -9 | -9.5 | -8.1 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
31.6B USD | 3.2 | 27.2 | 14.7 | 18.2 | |
| KR |
|
Celltrion Inc
KRX:068270
|
38.1T KRW | 17.5 | 71.1 | 43.5 | 59.9 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
